-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
【Pharmaceutical Network Market Analysis】On December 16, ABio announced that it has completed a $15 million seed round of financing
.
The round was co-led by Sequoia China Seed Fund and Eight Roads in collaboration with F-Prime Capital
.
The funds will be used to build and serve as a platform for innovation discovery and to advance the company's current lead drug candidates for the toughest
cancers.
It is understood that EverBio is a privately held biotechnology company that develops new drugs targeting chemically modified processing enzymes, and has expertise in signal transduction, gene expression regulation, cancer biology and drug discovery
.
On December 5, Qingke Biotech received 400 million yuan in financing
.
This round of financing is mainly used for the R&D investment, technology platform upgrade and talent team expansion of Qingke Biogene Factory, as well as the layout of promoting international operation to create an intelligent and automated production platform
that meets global standards.
Prior to this, Guosen Pharmaceutical also announced the completion of a series B+ financing of nearly 100 million yuan, after the completion of this round of financing, the company will continue to focus on and deepen the clinical research of innovative drugs in cutting-edge pipelines, deepen business and technology, and continue to highlight the advantages
in the field of cell and gene therapy (CGT).
According to the data, Guosen Pharma focuses on innovative drugs, cell and gene therapy clinical CRO services, and has become the head clinical CRO
in the field of cell and gene therapy (CGT) in China.
In addition to the above companies, since 2022, a large number of pharmaceutical companies have also obtained financing
.
According to data, since November, the net purchase of A-share financing has reached more than
28 billion yuan.
As of November 21, the financing balance of the two cities was 1.
47 trillion yuan
.
In terms of industries, the five major industries such as medicine and biology, power equipment, computers, electronics, and basic chemicals have financed net purchases of more than 2 billion yuan
since November.
Among them, the net purchase amount of pharmaceutical and biological financing was nearly 10.
4 billion yuan, making it an industry
with a high amount of financing funds.
Since December, pharmaceutical and biological financing has also been very active
.
Statistics show that of the 28 primary industries to which Shenwan belongs, a total of 12 industry sectors received net purchases of financing on December 13, and 5 of them had a net purchase amount of more than 100 million yuan
.
Among them, the pharmaceutical and biological industry ranked first in net purchases of financing, with a net purchase of 1.
107 billion yuan
on the day.
On December 5, 21 industry sectors received net buying
.
Among them, the pharmaceutical and biological industry also led the net purchase of financing, with a net purchase of nearly 1.
2 billion yuan on the day, reaching 1.
183 billion yuan
.
Industry analysts believe that the support of many favorable policies and the entry of a large amount of capital are accelerating the development of high-quality innovation in the pharmaceutical and biological industry
.
Affected by this, the pharmaceutical and biological sector began to rebound strongly, and the financing funds increased significantly
.
For example, last month, the pharmaceutical biology index rose by more than 6%.
During this period, more than ninety percent of pharmaceutical stocks recorded a rise, among which Teyi Pharmaceutical, Wonder Pharmaceutical, Zhongsheng Pharmaceutical, Hendi Pharmaceutical, Tailong Pharmaceutical, etc.
rose by more than 50%, becoming popular stocks
sought after by market funds.
In the context of the bottom of the medical insurance centralized procurement policy and the gradual elimination of the influencing factors that suppress the valuation of the pharmaceutical industry, analysts pointed out that the upward performance and valuation repair will bring continuous upward momentum
to the pharmaceutical and biological industry.
In the future, a large number of internationally competitive Chinese biomedical innovation enterprises are expected to emerge, helping China's pharmaceutical bio-innovation industry to accelerate its high-quality development
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.